The importance of the Akt pathway in EGFR-TKI resistance was validated in clinical samples from EGFR-mutant NSCLC patients, where phosphorylation of Akt was observed in 60% of tumor samples from patients after progression on EGFR TKIs, but only in 11% of baseline samples. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.